Compass Pathways Plc
Research Compass Pathways Plc (CMPS) on Bullrun: market cap USD 2.02B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCMPS
- ExchangeNASDAQ
- CountryUnited Kingdom
- SectorHealthcare
- IndustryMedical Care Facilities
- CurrencyUSD
- Market capUSD 2.02B
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 253.79M
- Free cash flow-USD 40.31M
Valuation Snapshot
latest market cap is USD 2.02B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 269.77M | -USD 157.24M | n/a | -3.08 | USD 149.61M | USD 31.63M | -USD 52.85M |
| FY2024 | USD 0 | -USD 155.12M | -USD 119.19M | n/a | -2.3 | USD 165.08M | USD 30.17M | USD 154.70M |
| FY2023 | n/a | -USD 118.46M | -USD 97.44M | n/a | -2.32 | USD 220.20M | USD 28.76M | USD 225.74M |
| FY2022 | n/a | -USD 91.51M | -USD 106.05M | n/a | -2.16 | USD 143.21M | USD 0 | USD 181.28M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 2.02B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 662.99M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 259.13M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 541.59M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 341.89M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 928.64M | n/a | n/a | n/a |
About Compass Pathways Plc
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Compass Pathways Plc's market cap?
Compass Pathways Plc's market capitalization is USD 2.02B.
What does Compass Pathways Plc do?
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.